InsiderSignal.AI

InsiderSignal.ai

ABSI - Absci Corp

Insider Purchase by Busch Andreas (Chief Innovation Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Busch Andreas, serving as Chief Innovation Officer at Absci Corp (ABSI), purchased 100,000 shares at $2.29 per share, for a total transaction value of $229,000.00. Following this transaction, Busch Andreas now holds 421,446 shares of ABSI.

This purchase represents a 31.00% increase in Busch Andreas's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, March 12, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 4 days after the trade was made.

Absci Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Busch Andreas

Chief Innovation Officer

Andreas Busch, Ph.D., is Chief Innovation Officer at Absci Corporation (ABSI), a role he has held since September 2022, employed via Absci GmbH. Age 61 as of March 31, 2025, he leads R&D, technical operations, and drives internal and partner programs at the generative AI drug creation company.[[1]](https://fintool.com/app/research/companies/ABSI/people/andreas-busch)[[2]](https://www.frontiers.health/speaker/andreas-busch)[[4]](https://www.absci.com/about-us/team/) Under his tenure, Absci achieved 100% of corporate performance goals in 2023 and 2024, encompassing pipeline advancement, strategic partnerships, R&D milestones, AI platform development, and cash flow objectives.[[1]](https://fintool.com/app/research/companies/ABSI/people/andreas-busch) Busch brings extensive expertise from senior R&D leadership roles at major pharma companies, including Chief Scientific Officer and Chief Innovation Officer at Cyclerion Therapeutics (2019–2022), EVP and Head of R&D at Shire (2018–2019), Executive VP and Global Head of Drug Discovery at Bayer (2006–2017), and Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. His leadership has resulted in over 10 commercial drugs from bench to FDA approval, with several more in late-stage clinical development.[[1]](https://fintool.com/app/research/companies/ABSI/people/andreas-busch)[[2]](https://www.frontiers.health/speaker/andreas-busch)[[3]](https://www.youtube.com/watch?v=G191QnDPDNA) He holds an Extraordinary Professorship in Pharmacology at Goethe University Frankfurt, where he earned his Ph.D., and serves on boards of institutions like the German Cancer Research Center and companies including Astellas Pharma.[[1]](https://fintool.com/app/research/companies/ABSI/people/andreas-busch)[[2]](https://www.frontiers.health/speaker/andreas-busch)[[5]](https://www.marketscreener.com/insider/ANDREAS-BUSCH-A0H5J5/)

View full insider profile →

Trade Price

$2.29

Quantity

100,000

Total Value

$229,000.00

Shares Owned

421,446

Trade Date

Thursday, March 12, 2026

6 days ago

SEC Filing Date

Monday, March 16, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Absci Corp

Company Overview

No company information available
View news mentioning ABSI

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4838751

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime